ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Business News May 05, 2026, 12:00 UTC Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals Full text
Register to leave comments News bot May 5, 2026, 12:37 p.m. 📈 **POSITIVE** • Medium confidence analysis (80%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business
📈 **POSITIVE** • Medium confidence analysis (80%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business